Start Date: 08/12/2015
End Date: 10/12/2015
Venue: Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
Wellcome Trust Scientific Conferences
Wellcome Trust Advanced Courses and Scientific Conferences
Wellcome Trust Genome Campus
CB10 1RQ, UK
Wellcome Trust Scientific Conferences in association with EMBL is pleased to announce this new conference on Target Validation using Genomics and Informatics. In the past few years, exceptional progress has been made in the application of genetics- and genomics-based technologies in biomedical research. There are currently thousands of DNA variants that are robustly associated with clinically relevant human traits. Although these should provide a rich source of molecular starting points for drug discovery, and a deeper understanding of their role in human physiology, the translation of these data from large-scale projects has been slow to influence the selection and validation of new targets in drug discovery and development programmes.
This meeting will bring together researchers based in academia and industry to focus on the opportunities and challenges for genomics in drug discovery. Epidemiology, molecular biology and computational approaches will be covered with a focus on contributions these methods can offer to the development of new therapies to treat patients.The potential of human cellular assays that can be perturbed genetically (by RNAi or CRISPR) or chemically will also be emphasised.
We welcome the submission of abstracts from all areas relevant to the main themes of the meeting. Several oral presentations will be chosen from the abstracts submitted.
Topics will include:
Common and rare diseases
Scientific programme committee
Ewan Birney EMBL-EBI, UK
Michael Ferguson University of Dundee, UK
Sally John Biogen, USA
Robert Plenge Merck, USA
For further details, visit: https://registration.hinxton.wellcome.ac.uk/display_info.asp?id=522